Inhibrx Biosciences, Inc. (INBX)
90.53
-4.48
(-4.72%)
USD |
NASDAQ |
Oct 12, 16:00
90.46
-0.07
(-0.08%)
After-Hours: 20:00
Inhibrx Biosciences Total Assets (Quarterly) : 154.22M for June 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 154.22M |
| March 31, 2026 | 183.97M |
| December 31, 2025 | 146.48M |
| September 30, 2025 | 177.47M |
| June 30, 2025 | 212.12M |
| March 31, 2025 | 242.64M |
| Date | Value |
|---|---|
| December 31, 2024 | 180.77M |
| September 30, 2024 | 222.56M |
| June 30, 2024 | 258.42M |
| March 31, 2024 | 288.58M |
| December 31, 2023 | 307.89M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Agenus, Inc. | 172.69M |
| Amgen, Inc. | 95.64B |
| Anika Therapeutics, Inc. | 183.47M |
| BioCryst Pharmaceuticals, Inc. | 557.85M |
| Imunon, Inc. | 14.99M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 207.20M |
| Shareholders Equity (Quarterly) | -52.98M |
| Debt to Equity Ratio | -3.428 |
| Current Ratio | 5.067 |
| Net Debt Paydown Yield | -1.08% |